Health written statement – made at on 3 September 2013.
Norman Lamb
The Minister of State, Department of Health
I regret that the written answer given to Nicholas Soames on
It has been brought to my attention that the information provided in the original answer did not contain secondary care figures for December 2012. The table below shows the correct figures. The revised answer is as follows:
Expenditure by national health service trusts in London, as defined by the former London Special Health Authority (SHA), is provided for both anti-retroviral HIV medicines and anti-cancer medicines.
London generally has a larger proportion of its medicines costs going through hospitals than other SHAs as patients from areas surrounding London are likely to travel to London hospitals for some treatments.
| Primary care cost(1) | Secondary care cost(2) | ||
| Drug type | Year | (£000s) | (£000s) |
| Anti-retroviral HIV(3) | 2008 | 321.0(4) | 175,398.3 |
| 2009 | 502.4 | 191,720.7 | |
| 2010 | 642.0 | 206,752.9 | |
| 2011 | 555.5 | 214,542.6 | |
| 2012 | 539.4 | 233,949.2 | |
| Anti-cancer(5) | 2008 | 17,299.8(4) | 112,677.5 |
| 2009 | 23,486.3 | 131,052.7 | |
| 2010 | 22,461.9 | 147,571.4 | |
| 2011 | 20,958.7 | 157,944.3 | |
| 2012 | 13,017.2(6) | 188,663.9 | |
| Sources Prescribing Analysis and Cost tool (PACT) system. Copyright © 2013, the Health and Social Care Information Centre, Prescribing and Primary Care Services. IMS data. Copyright © IMS HEALTH: Hospital Pharmacy Audit. Some supplies through homecare providers may not be capture,d therefore cost estimates may be under-stated. Notes (1)Net ingredient cost. (2)Cost of medicines at NHS list price and not necessarily the price paid. (3)As classified within British National Formulary (BNF) section 5.3.1 HIV infection. (4)Information for 2008 primary care costs is only available for May to December 2008. (5)As classified within British National Formulary (BNF) section 8.1 Cytotoxic drugs, paragraph 8.2.3 Anti-lymphocyte monoclonal antibodies, paragraph 8.2.4 Other immunomodulating drugs (Aldesleukin, Bacillus Calmette-Guerin (B.C.G.), Lenalidomide and Thalidomide (immunomodulating) only), section 8.3 Sex hormones and hormone antagonists in malignant disease. (6)The main reason for the lower cost is the large reduction in the cost per item price for three drugs, as lower-cost generic formualions became available (Anastrozole, Exemestane and Letrozole). These are mainly used in primary care; therefore there was not the comparable reduction in secondary care costs. | |||
